SynthesisFrontiers in oncology2025
Two decades of progress in gastric cancer peritoneal metastasis: a bibliometric perspective on molecular mechanisms and therapeutic innovations.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- m6A-methylated circFANCB Promotes Gastric Cancer Progression by Regulating Cellular Ferroptosis Through miR-454-3p/CEACAM5.Journal of biochemical and molecular toxicology · 2026Article
- Delayed phase dual-energy CT for early peritoneal metastasis prediction: imaging phenotypes and tumor-stroma correlates in upfront gastrectomy candidates.Abdominal radiology (New York) · 2026Article
- TRIM47: molecular characteristics, disease-related mechanisms, and clinical translational value.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is the fifth most common malignant tumor worldwide. The peritoneum is a common site of metastasis in advanced GC, and patients with gastric cancer peritoneal metastasis (GCPM) have a very low 5-year survival rate. Systemic therapy has limited efficacy for peritoneal metastases, and early diagnosis is difficult. In this paper, we analyzed the GCPM-related literature by bibliometric methods, aiming to identify the research hotspots and trends and to provide a basis for clinical practice and research planning. Methods: Based on the Web of Science Core Collection database (WoSCC), we screened the GCPM-related literature published from 2004 to 2024. Countries, institutions, authors, journals, and keywords were analyzed and visualized by tools such as CiteSpace, VOSviewer, Scimago Graphica, RStudio, and the Bibliometrix package. Result: A total of 2416 publications were included in this study. The growth rate of GCPM publications is positive until 2021, with a slowdown in the near future. Japan dominated the research output (842 publications), followed by China (748 publications) and the United States (268 publications). Japanese-affiliated organizations and researchers are extremely productive in the field of GCPM. The most frequently cited document was Japanese gastric cancer treatment guidelines 2014 (ver. 4) (citations = 2076). Research focuses on four major clusters: (1) molecular mechanisms of GCPM; (2) prognosis of GCPM; (3) chemotherapy of GCPM; and (4) intraperitoneal treatment of GCPM. Emerging trends include key pathways of GCPM, artificial intelligence (AI) and multi-omics-driven early diagnosis, novel intraperitoneal therapeutic modalities, and immunologic/targeted drugs. Conclusion: Japan is a leader in GCPM research. Recently, the focus of GCPM research has shifted from basic treatment to precision and personalized treatment through the integration of molecular mechanisms, novel intraperitoneal therapeutic modalities, and AI technologies. Current challenges include the lack of standardized validation systems for emerging technologies and regional differences in clinical practice. In the future, there is a need to promote global collaborative trials and optimization of multimodality therapy. The results of this study provide a key direction and systematic basis for future exploration of GCPM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.